POSA70 Budget Impact Analysis of Avelumab Plus Best Supportive Care (BSC) vs BSC Alone as First-Line (1L) Maintenance Treatment in Patients With Locally Advanced (LA) or Metastatic Urothelial Carcinoma (mUC) in Taiwan
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.215
https://www.valueinhealthjournal.com/article/S1098-3015(21)02010-6/fulltext
Title :
POSA70 Budget Impact Analysis of Avelumab Plus Best Supportive Care (BSC) vs BSC Alone as First-Line (1L) Maintenance Treatment in Patients With Locally Advanced (LA) or Metastatic Urothelial Carcinoma (mUC) in Taiwan
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02010-6&doi=10.1016/j.jval.2021.11.215
First page :
Section Title :
Open access? :
No
Section Order :
10986